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Objectives
Despite very low rates of vertical transmission of HIV in the UK overall, rates are higher among women
starting antenatal antiretroviral therapy (ART) late. We investigated the timing of key elements of the
care of HIV-positive pregnant women [antenatal care booking, HIV laboratory assessment (CD4 count
and HIV viral load) and antenatal ART initiation], to assess whether clinical practice is changing in line
with recommendations, and to investigate factors associated with delayed care.
Methods
We used the UK’s National Study of HIV in Pregnancy and Childhood for 20092014. Data were
analysed by fitting logistic regression and Cox proportional hazards models.
Results
A total of 5693 births were reported; 79.5% were in women diagnosed with HIV prior to that
pregnancy. Median gestation at antenatal booking was 12.1 weeks [interquartile range (IQR)
10.0–15.6 weeks] and booking was significantly earlier during 2012–2014 vs. 2009–2011
(P < 0.001), although only in previously diagnosed women. Overall, 42.2% of pregnancies were
booked late (≥ 13 gestational weeks). Among women not already on treatment, antenatal ART
commenced at a median of 21.4 (IQR18.1–24.5) weeks and started significantly earlier in the most
recent time period (P < 0.001). Compared with previously diagnosed women, those newly
diagnosed during the current pregnancy booked later for antenatal care and started antenatal ART
later (both P < 0.001). Multivariable analyses revealed demographic variations in access to or
uptake of care, with groups including migrants and parous women initiating care later.
Conclusions
Although women are accessing antenatal and HIV care earlier in pregnancy, some continue to face
barriers to timely initiation of antenatal care and ART.
Keywords: antenatal care, antiretroviral therapy, HIV, pregnancy, prevention of mother-to-child
transmission.
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Introduction
Improvements in antiretroviral therapy (ART) and obstet-
ric care have contributed to the lowest ever rate of
mother-to-child transmission of HIV (MTCT) of 0.5% in
the UK and Ireland in recent years [1]. However, MTCT
rates are higher in some groups of women, such as those
starting ART late in pregnancy [1]. There are currently
around 12001300 pregnancies to diagnosed HIV-posi-
tive women in the UK annually [2]; optimizing their care
is important not only to prevent transmission of HIV to
their children, but also to ensure good maternal health,
and the best possible pregnancy outcome.
The antenatal ‘booking’ appointment is generally the
first contact pregnant women have with maternity ser-
vices, and provides an opportunity for the identification
of maternal and familial risk factors, the offer of timely
antenatal screening, and an opportunity to communicate
important information to women [3]. Early booking is
particularly important for women living with HIV,
whether diagnosed before or during the pregnancy, to
ensure that they receive the HIV-specific care they
require in a timely manner, including assessment of
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clinical and virological status, and initiation of ART for
those not already on treatment.
Current international and UK guidelines recommend
earlier initiation of antenatal ART than previously [4,5].
Identifying population groups at increased risk of late
antenatal booking and ART initiation will help target
efforts towards ensuring equity in access to and uptake of
care. Our objective was to investigate the timing of key
elements of care of HIV-positive pregnant women in the
UK [antenatal care booking, HIV laboratory assessment
(CD4 count and HIV viral load) and antenatal ART initia-
tion], to assess whether clinical practice has changed in
line with the recommendations, and to investigate factors
associated with delayed antenatal booking and initiation
of antenatal ART.
Methods
Data source
The National Study of HIV in Pregnancy and Childhood
(NSHPC) is a well-established, comprehensive, active
surveillance study covering the UK and Ireland. Demo-
graphic, clinical and obstetric information is collected
using standardized reporting forms [6].
Definitions and classifications
Data on UK pregnancies only, resulting in a live or still
birth delivered from 1 January 2009 onwards, and
reported by the end of June 2014, were utilized. Some
degree of reporting delay is to be expected for pregnan-
cies occurring in more recent years. Pregnancies without
information on the timing of HIV diagnosis were
excluded (n = 10). Two calendar periods, 2009–2011 and
2012–2014, were compared to examine changes over
time; the earlier period was covered by the 2008 British
guidelines recommending antenatal ART initiation by 28
gestational weeks [7], and the second by 2012 guidelines
recommending ART initiation by 24 weeks [4]. Both
guidelines recommended earlier initiation in women
requiring treatment for their own health, and those
with high viral loads. We defined late antenatal care
booking as booking at ≥ 13 completed gestational
weeks, in line with general pregnancy guidelines [3,8].
Analyses were stratified by the timing of HIV diagnosis:
pregnancies in previously diagnosed women (further
stratified according to ART status at conception where
appropriate) and those in women diagnosed after con-
ception (‘newly diagnosed’).
Assessment of the timing of the earliest laboratory test
was restricted to newly diagnosed women and based on
reported date of earliest CD4 count or viral load test (re-
stricted to those taken between 14 days prior to concep-
tion and 7 days after delivery). Baseline (pre-ART)
measurements were further restricted to those prior to or
up to 7 days after ART initiation (≤ 7 days after delivery
in women receiving no antenatal ART). Viral load mea-
surements were grouped reflecting cut-offs for recom-
mended timing of ART initiation in women not requiring
treatment for their own health [4]. Analyses of timing of
antenatal ART initiation were, by definition, restricted to
pregnancies not conceived on treatment.
Statistical methods
Data were analysed using STATA 12.1 (Stata Corp., Col-
lege Station, TX). Proportions were calculated among
those with known information on the variable of inter-
est and compared using the v2 test or v2 test for trend.
Medians are presented with interquartile range (IQR) and
were compared using the WilcoxonMannWhitney
test.
Logistic regression models were fitted to identify fac-
tors associated with late antenatal care booking. Kaplan–
Meier analysis was used to describe time to ART initia-
tion graphically, and factors associated with later antena-
tal ART initiation were analysed using Cox proportional
hazards modelling. The proportional hazards assumption
was assessed by examining log-log plots and the model’s
Schoenfeld residuals [9]. The TherneauGrambsch test
was significant both globally and locally for time period,
CD4 count and viral load in both strata; this is not sur-
prising given the relatively large sample sizes. There was
evidence of nonparallelism and crossings in the log-log
plots; however, these were mainly in the lower and
upper tails of the distribution of time to ART initiation
(and thus related to relatively small numbers of women),
while the central part of this distribution showed little
evidence of departures from the assumption. Variables
with overall significance at the P < 0.1 level in univari-
able analyses were included in multivariable models,
with other variables only included if they improved the
fit (assessed using the Wald test). Time period was
included a priori. Some women with a prior diagnosis
contributed more than one pregnancy to these analyses,
and this clustering was accounted for by using robust
standard errors [10].
Ethical approval
The National Study of HIV in Pregnancy and Childhood
has London Multi-Centre Research Ethics Committee
approval (MREC/04/2/009).
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Results
Study population
By the end of June 2014, 5693 eligible pregnancies had
been reported (5641 live and 52 still births) in 4962
women (3506 deliveries in 2009–2011 and 2187 in 2012–
2014). Overall, 2886 (50.7%) pregnancies were among
women conceiving on ART, 1601 (28.1%) among diag-
nosed women not on ART at conception and 1166
(20.5%) among women newly diagnosed during the cur-
rent pregnancy; the remaining 40 pregnancies were to
women diagnosed before conception, but missing infor-
mation on ART status at conception (Table 1). The
proportion of pregnancies in women with previously
diagnosed HIV increased from 76.6% in 2009–2011 to
84.2% in 2012–2014 (P < 0.001). Overall, most pregnan-
cies were in women from sub-Saharan Africa (75.3%),
over two-fifths were reported in London, nearly three-
quarters were in parous women, and half were conceived
on ART.
Timing of booking for antenatal care
Booking date was reported for 5162 (90.7%) pregnancies.
It was less well reported for pregnancies from London
compared with the rest of England (P < 0.001), and
Table 1 Pregnancy characteristics stratified by timing of HIV diagnosis
Characteristic
Diagnosed prior
to current pregnancy -
not on ART at conception
Diagnosed prior
to current pregnancy -
on ART at conception
Diagnosed prior
to current pregnancy
(irrespective of ART
status)*
Newly diagnosed
during current
pregnancy
Total (all
pregnancies)
Total 1601 2886 4527 1166 5693 (100)
Time period
2009–2011 1049 (65.5) 1611 (55.8) 2686 (59.3) 820 (70.3) 3506 (61.6)
2012–2014 552 (34.5) 1275 (44.2) 1841 (40.7) 346 (29.7) 2187 (38.4)
Maternal age at delivery
< 25 years 209 (13.1) 140 (4.9) 355 (7.8) 177 (15.2) 532 (9.3)
25–34 years 967 (60.4) 1479 (51.2) 2472 (54.6) 727 (62.3) 3199 (56.2)
≥ 35 years 425 (26.5) 1267 (43.9) 1700 (37.6) 262 (22.5) 1962 (34.5)
Maternal region of origin
UK/Ireland 276 (17.4) 331 (11.6) 612 (13.7) 157 (13.7) 769 (13.7)
Europe 80 (5.0) 107 (3.8) 190 (4.2) 77 (6.7) 267 (4.8)
Eastern Africa 642 (40.5) 1386 (48.7) 2048 (45.8) 397 (34.7) 2445 (43.5)
Middle Africa 100 (6.3) 190 (6.7) 293 (6.6) 49 (4.3) 342 (6.1)
Western Africa 311 (19.6) 498 (17.5) 813 (18.2) 301 (26.3) 1114 (19.8)
Southern Africa 77 (4.9) 130 (4.6) 209 (4.7) 61 (5.3) 270 (4.8)
Africa (unspecified) 11 (0.7) 30 (1.1) 41 (0.9) 18 (1.6) 59 (1.1)
Elsewhere 88 (5.6) 174 (6.1) 265 (5.9) 85 (7.4) 350 (6.2)
Reporting region
London 641 (40.2) 1279 (44.4) 1926 (42.6) 488 (42) 2414 (42.5)
Midlands and the East 409 (25.6) 649 (22.5) 1073 (23.8) 284 (24.4) 1357 (23.9)
North 253 (15.9) 414 (14.4) 677 (15) 153 (13.2) 830 (14.6)
South 189 (11.8) 394 (13.7) 591 (13.1) 150 (12.9) 741 (13.1)
Wales, Scotland and Northern Ireland 103 (6.5) 145 (5) 249 (5.5) 87 (7.5) 336 (5.9)
Parity
Nulliparous 300 (19.6) 559 (20.4) 864 (20.1) 555 (50.7) 1419 (26.3)
One previous birth 592 (38.7) 1018 (37.2) 1626 (37.9) 323 (29.5) 1949 (36.2)
Two previous births 400 (26.1) 740 (27.0) 1145 (26.7) 145 (13.2) 1290 (23.9)
At least three previous births 238 (15.6) 419 (15.3) 660 (15.4) 72 (6.6) 732 (13.6)
Earliest CD4 count†
≥ 500 cells/lL 484 (33.1) 1163 (44.2) 1654 (40.3) 306 (27.9) 1960 (37.7)
350–499 cells/lL 432 (29.5) 800 (30.4) 1238 (30.2) 258 (23.6) 1496 (28.8)
200–349 cells/lL 368 (25.2) 517 (19.7) 886 (21.6) 317 (28.9) 1203 (23.1)
< 200 cells/lL 178 (12.2) 149 (5.7) 327 (8.0) 214 (19.5) 541 (10.4)
Earliest viral load†
< 50 copies/mL 275 (18.1) 2350 (85.9) 2641 (61.8) 145 (12.8) 2770 (51.4)
50–29 999 copies/mL 931 (61.4) 342 (12.5) 1279 (29.9) 700 (61.6) 1973 (36.6)
30 000–99 999 copies/mL 213 (14.0) 25 (0.9) 238 (5.6) 168 (14.8) 406 (7.5)
≥ 100 000 copies/mL 98 (6.5) 18 (0.7) 116 (2.7) 124 (10.9) 240 (4.5)
ART, antiretroviral therapy.
Values are n (%).
*Group combines the first two groups presented in the table (n = 1601 + 2886) plus 40 pregnancies with missing information on ART status at con-
ception.
†Earliest antenatal measurement in that pregnancy, not restricted to measurements taken prior to ART initiation.
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better reported for pregnancies in parous women
(P < 0.001). Gestational age at booking had a right-
skewed distribution, with a median (IQR) of 12.1 (10.0–
15.6) weeks. Overall, 42.2% of pregnancies were booked
late at ≥ 13 completed weeks: 25.7% at 13–17 weeks,
10.0% at 18–23 weeks, and 6.6% at ≥ 24 weeks. The
proportion of pregnancies booked late declined from
44.8% in 2009–2011 to 38.2% in 2012–2014 (P < 0.001),
although only in previously diagnosed women. Pregnan-
cies in previously diagnosed women were booked earlier
than those in newly diagnosed women at a median of
12.0 (9.7–14.9) weeks compared with 13.1 (10.6–18.0)
weeks (P < 0.001), respectively (Fig. 1a,b); 39.7% of
pregnancies in previously diagnosed women were booked
late at ≥ 13 weeks (including 14.2% at ≥ 18 weeks),
compared with 51.9% (25.7% at ≥ 18 weeks) in newly
diagnosed women (both P < 0.001). In previously diag-
nosed women, there was no association between gesta-
tional age at booking and CD4 count (P = 0.33).
In univariable analyses, maternal region of origin, UK
geographical area of report, and parity were significantly
associated with late booking in pregnancies to both pre-
viously and newly diagnosed women (Table 2). Addition-
ally, in pregnancies to previously diagnosed women,
earlier time period, low antenatal CD4 count and not
conceiving on ART were associated with increased odds
of late booking.
Both multivariable models included all variables from
the univariable analyses, except maternal age and viral
load, which did not improve the fit (Table 2). In multi-
variable analyses of pregnancies in previously diag-
nosed women, late booking was associated with earlier
time period, originating from abroad (including Euro-
pean-born women and those from all regions of sub-
Saharan Africa), pregnancy reported from outside Lon-
don, being parous, not conceiving on ART, and having
a low CD4 count. Among pregnancies to newly diag-
nosed women, late booking was associated with sub-
Saharan African origin (all regions), and higher parity.
The odds of late booking were lower for pregnancies
reported from elsewhere in England compared with
London.
In a sensitivity analysis of the association between
being born abroad and late antenatal booking which
excluded women known to have arrived in the UK at
≥ 13 gestational weeks (n = 86), the results were little
changed and the strong association between African ori-
gin and late booking, regardless of timing of diagnosis,
remained (data not shown).
Timing of first reported laboratory test (CD4 count or
viral load) in pregnancies among newly diagnosed
women
The timing of the first reported antenatal HIV-related lab-
oratory test was available for 1139 of 1166 (97.7%) preg-
nancies. It was at a median of 17.0 weeks of gestation
(IQR 13.4–23.4 weeks), and the interval between concep-
tion and testing decreased between the two time periods
[median 17.4 (IQR 13.7–23.6) weeks in 2009–2011 and
16.0 (IQR 12.9–22.6) weeks in 2012–2014; P = 0.016].
Information on both antenatal booking date and date of
first antenatal laboratory test was available for 1044
pregnancies (89.5%). The laboratory test was on or after
the booking date in 908 of 1044 pregnancies; among
these, the median time from booking to laboratory assess-
ment was 2.9 weeks (IQR 1.3–5.9 weeks), with over a
third (343 of 908) having a lag of ≥ 4 weeks.
Timing of antenatal ART initiation
In almost all pregnancies, women received antenatal ART
(99.2%; 5620 of 5666), and in most this was combination
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Fig. 1 Gestation at antenatal care booking for (a) women diagnosed
with HIV prior to that pregnancy and (b) women newly diagnosed
with HIV during that pregnancy.
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ART (cART) (98.3%; 5507 of 5602; unspecified regimen
in 18). Just over half of all pregnancies were conceived
on treatment (n = 2886), and virtually all women not on
ART at conception started ART during pregnancy (98.3%;
2704 of 2750); start date was available for 2619 (1543
with prior diagnosis). Median gestation at ART initiation
among all those initiating ART in pregnancy was 21.4
(IQR 18.1–24.5) weeks [21.0 (IQR 17.6–24.1) weeks in pre-
viously diagnosed women, compared with 21.9 (IQR
18.7–25.0) weeks for newly diagnosed women;
P < 0.001] (Fig. 2). ART was started significantly earlier
in pregnancies delivered in 2012–2014 [median 20.3 (IQR
16.9–23.4) weeks] compared with 2009–2011 [median
22.0 (IQR 18.9–24.7) weeks; P < 0.001], a trend apparent
for both previously and newly diagnosed women (both
P < 0.001).
Among women not on ART at conception, the median
time from antenatal booking to ART initiation was 7.1
(IQR 2.9–11.1) weeks; 7.3 (IQR 2.6–11.6) weeks in those
previously diagnosed and 6.9 (IQR 3.0–10.9) weeks in
those newly diagnosed. Among pregnancies to newly
diagnosed women, the median gap from laboratory test-
ing to ART initiation was 3.0 (IQR 0.3–6.6) weeks. The
time from laboratory testing to ART initiation was shorter
for pregnancies delivered in 2012–2014 than for those
delivered in 2009–2011 [median 2.7 (IQR 0.1–6.0) vs. 3.0
(IQR 0.4–7.0) weeks, respectively; P = 0.03]; it was also
shorter for those with a pre-ART antenatal CD4 count of
< 350 vs. ≥ 350 cells/lL [median 2.7 (IQR 1.1–5.0) vs. 5.1
(IQR 2.0–9.1) weeks, respectively; P < 0.001], and those
with viral loads ≥ 30 000 HIV-1 RNA copies/mL [median
2.3 (IQR 0.9–4.7) weeks] compared with < 30 000 copies/
mL [median 4.3 (IQR 1.7–8.1) weeks] (P < 0.001).
In univariable analyses of factors associated with the
timing of antenatal ART initiation (Table 3), ART was
started significantly earlier for pregnancies delivered in
the later period compared with 2009–2011, regardless of
the timing of HIV diagnosis. Factors associated with
shorter time to ART initiation among previously diag-
nosed women were being reported outside London, hav-
ing a lower CD4 count and having a higher viral load.
There was a similar pattern for newly diagnosed women,
but additionally, there were differences according to
maternal age and world region of origin, with older
women starting ART earlier, and women from Western
Africa, in particular, starting later than UK/Irish-born
women.
In the multivariable model for pregnancies in previ-
ously diagnosed women (Table 3), later time period
remained associated with earlier ART initiation
(P < 0.001). Compared with London, ART was started
somewhat earlier in the North of England (P = 0.003) and
in Wales, Scotland and Northern Ireland (P = 0.035), and
women with at least three previous births started later
than nulliparous women (P = 0.013). There was some
suggestion that those with lower CD4 counts started ear-
lier than those with counts ≥ 500 cells/lL, but this only
reached statistical significance for those with counts of
200–350 cells/lL (P = 0.001). Those with viral loads
> 30 000 copies/mL started earlier than those with lower
viral loads (P < 0.01). There was no evidence that includ-
ing maternal age or world region of origin improved the
fit of the model. In a sensitivity analysis excluding
women known to have arrived in the UK after conception
(n = 10), the results were little altered.
For pregnancies in newly diagnosed women, the pat-
tern was similar, with ART started earlier in the later
period (P < 0.001). Women from Eastern, Western, and
Southern Africa started later than those from the UK/Ire-
land (all P < 0.05), with some evidence that women
from Europe did too (P = 0.068). ART was started earlier
in all regions/areas of the UK compared with London,
although this was only significant for the North of Eng-
land (P = 0.039). Lower CD4 counts were associated with
earlier ART. When pregnancies to women known to
have arrived in the UK after conception were excluded
(n = 54), similar patterns were observed, although there
was less evidence of an association between Eastern or
Southern African origin and later ART (P = 0.095 and
P = 0.081, respectively), while women from Western
Africa remained more likely to start ART later
(P = 0.004) (data not shown). Finally, when the model
was restricted to women who booked at < 13 weeks,
evidence remained that women born abroad initiated
ART later than those born in the UK/Ireland. In particu-
lar, women from Western Africa started later [adjusted
hazard ratio (aHR) 0.50; 95% confidence interval (CI)
Fig. 2 Cumulative probability of initiating antenatal antiretroviral
therapy (ART) by gestational week, stratified by timing of HIV diag-
nosis.
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0.34–0.74; P < 0.001], as did those from Southern Africa
(P = 0.05).
Infant HIV status
HIV status was reported for 3988 infants by the time of
this analysis – 16 were perinatally infected (half of whom
were born to women with a prior diagnosis). Three-quar-
ters of perinatally infected infants (n = 12) were born to
women who booked late, 11 of whom were not on ART
at conception.
Discussion
During the study period, the vast majority (99%) of
women received antenatal ART, median gestation at
antenatal ART initiation declined over time, and women
with high viral loads started ART earlier, in line with
changes to UK recommendations [4]. Longer duration of
antenatal ART is associated with a lower risk of vertical
transmission of HIV, with a rapid decline in maternal
viral load during the first few weeks of ART [1,11]. The
crude vertical transmission rate for deliveries during
Table 3 Univariable and multivariable Cox proportional hazards analyses of factors associated with shorter time to antenatal antiretroviral
therapy (ART) initiation, stratified by timing of HIV diagnosis
Characteristic
Diagnosed prior to current pregnancy Newly diagnosed during current pregnancy
n HR (95% CI) P-value aHR (95% CI)* P-value n HR (95% CI) P-value aHR (95% CI)† P-value
Time period
2009–2011 1022 1 1 796 1 1
2012–2014 521 1.24 (1.10–1.39) < 0.001 1.28 (1.12–1.46) < 0.001 326 1.20 (1.05–1.37) 0.006 1.34 (1.15–1.55) < 0.001
Maternal age at delivery
< 25 years 203 1 173 1 1
25–34 years 932 0.98 (0.83–1.16) 0.800 – 701 1.12 (0.95–1.33) 0.185 1.15 (0.95–1.40) 0.159
≥ 35 years 408 0.97 (0.81–1.16) 0.734 – – 248 1.31 (1.08–1.60) 0.007 1.17 (0.93–1.47) 0.192
Maternal region of origin
UK/Ireland 270 1 – 154 1 1
Europe 78 1.09 (0.85–1.41) 0.483 – – 71 0.87 (0.66–1.16) 0.357 0.75 (0.55–1.02) 0.068
Eastern Africa 616 1.05 (0.90–1.23) 0.520 – – 385 0.93 (0.77–1.13) 0.473 0.75 (0.60–0.93) 0.010
Middle Africa 96 0.96 (0.73–1.26) 0.784 – – 45 0.91 (0.65–1.27) 0.591 0.82 (0.56–1.20) 0.309
Western Africa 303 0.93 (0.78–1.11) 0.436 – – 294 0.73 (0.60–0.89) 0.002 0.60 (0.48–0.76) < 0.001
Southern Africa 74 1.08 (0.86–1.35) 0.499 – – 58 0.77 (0.56–1.04) 0.090 0.68 (0.47–0.97) 0.032
Africa (region unspecified) 10 1.01 (0.68–1.51) 0.951 – – 15 0.98 (0.58–1.67) 0.939 0.50 (0.25–1.00) 0.049
Elsewhere 83 1.02 (0.80–1.31) 0.881 – – 81 1.17 (0.89–1.54) 0.249 0.92 (0.68–1.25) 0.612
Reporting region
London 621 1 1 473 1 1
Midlands and the East 394 1.17 (1.02–1.33) 0.021 1.13 (0.96–1.32) 0.131 265 1.16 (1.00–1.35) 0.054 1.12 (0.93–1.35) 0.236
North 240 1.28 (1.10–1.48) 0.001 1.31 (1.10–1.57) 0.003 153 1.28 (1.07–1.54) 0.008 1.25 (1.01–1.55) 0.039
South 183 1.11 (0.94–1.31) 0.219 1.00 (0.82–1.22) 0.994 144 1.22 (1.01–1.47) 0.038 1.19 (0.94–1.50) 0.140
Wales, Scotland and
Northern Ireland
99 1.21 (0.98–1.50) 0.079 1.32 (1.02–1.71) 0.035 84 1.24 (0.98–1.57) 0.068 1.20 (0.93–1.55) 0.165
Parity
Nulliparous 289 1 1 538 1 –
One previous birth 569 0.89 (0.77–1.03) 0.120 0.98 (0.82–1.16) 0.782 312 1.00 (0.87–1.15) 0.971 – –
Two previous births 389 0.90 (0.77–1.05) 0.192 0.94 (0.79–1.13) 0.525 141 1.04 (0.86–1.25) 0.682 – –
At least three
previous births
226 0.72 (0.59–0.87) 0.001 0.77 (0.63–0.95) 0.013 68 0.98 (0.76–1.26) 0.852 – –
Baseline CD4 count‡
≥ 500 cells/lL 388 1 1 253 1 1
350–499 cells/lL 341 1.15 (1.01–1.30) 0.036 1.13 (0.97–1.32) 0.109 225 1.04 (0.87–1.25) 0.647 1.02 (0.84–1.23) 0.871
200–349 cells/lL 288 1.38 (1.17–1.63) < 0.001 1.32 (1.12–1.55) 0.001 280 1.24 (1.04–1.47) 0.015 1.31 (1.09–1.58) 0.003
< 200 cells/lL 144 1.30 (1.02–1.65) 0.032 1.16 (0.93–1.45) 0.199 191 1.54 (1.28–1.86) < 0.001 1.53 (1.23–1.91) < 0.001
Baseline viral load‡§
< 30 000 copies/mL 899 1 1 679 1 1
30 000–99 999 copies/mL 207 1.27 (1.09–1.49) 0.002 1.24 (1.05–1.46) 0.013 159 1.14 (0.96–1.36) 0.130 1.01 (0.83–1.23) 0.904
≥ 100 000 copies/mL 90 1.56 (1.13–2.16) 0.007 1.43 (1.11–1.85) 0.006 119 1.32 (1.08–1.60) 0.006 1.21 (0.96–1.51) 0.103
aHR, adjusted hazard ratio; CI, confidence interval; HR, hazard ratio.
An HR of > 1 indicates a shorter time to ART initiation.
*The multivariable model for pregnancies in previously diagnosed women included 1074 observations (and analyses were adjusted for 996 clusters; i.e.
the 1074 pregnancies occurred in 996 women).
†The multivariable model for pregnancies in women diagnosed during their current pregnancy included 903 observations.
‡First antenatal measurement in that pregnancy, restricted to measurements prior to ART initiation.
§Viral load grouping based on cut-offs used for recommending timing of ART initiation in women not requiring treatment for their own health [4.]
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2009–2014 is consistent with the previously published
UK rate of 0.46% for 2010/2011 [1]. Although there was
a trend towards earlier booking for antenatal care
(among previously but not newly diagnosed women),
over two-fifths of pregnancies in HIV-positive women
were booked at ≥ 13 weeks (38% for 2012–2014), com-
pared with 28% of pregnancies in England overall during
2012–2013 [12]. Later booking among HIV-positive
women probably reflects the cultural and sociodemo-
graphic characteristics of this population, and these anal-
yses revealed some important demographic variations in
the timeliness of antenatal booking and antenatal ART
initiation.
Women from sub-Saharan Africa were more likely to
book late, irrespective of the timing of diagnosis; being
born outside the UK and/or being of non-white ethnicity
has been reported as a risk factor for later booking in the
general UK population [13–16], and also in the NSHPC
data [17]. US data show that women of black ethnicity
experience poorer antenatal care usage [18,19], as does
the French Perinatal Cohort [20]. This may in part reflect
differing cultural beliefs around antenatal care [21], as
well as possible barriers to accessing care, including lack
of knowledge about the health care system and language
difficulties [13,22]. Culturally appropriate promotion of
antenatal care services among ethnic minority women in
the UK is one approach that may be beneficial [23].
Newly diagnosed women born abroad also started ART
later than those born in the UK/Ireland (there was no
such association among those previously diagnosed), and
this was particularly apparent among women from Wes-
tern Africa. This association persisted in several sensitiv-
ity analyses, indicating that it was not simply related to
women arriving in the UK late in pregnancy, nor just a
reflection of late presentation for antenatal care. In previ-
ously diagnosed women, late booking was more common
outside London, whereas for newly diagnosed women,
late booking was more common in London. Reasons are
unclear but may reflect the likely greater concentration
of newly arrived migrants in London who may have par-
ticular difficulties accessing health care.
Current UK standards state that positive HIV results
should be received by maternity services within 10 work-
ing days of the sample being taken and the result given
to women within 10 days of this, and that there should
be ‘urgent’ referral to the HIV specialist team thereafter
[24]. Although a majority of newly diagnosed women
had prompt laboratory assessment, over a third had a gap
of ≥ 4 weeks between booking and laboratory assessment.
Taking date of laboratory assessment as a proxy for first
appointment with the HIV specialist team, the finding
suggests that this is an area of practice that may need
improving. It is, however, encouraging that, on the
whole, newly diagnosed women started ART reasonably
promptly with respect to current UK guidelines [4]. Those
with lower CD4 counts started ART significantly sooner,
and those with lower CD4 counts or high viral loads had
shorter gaps from laboratory testing to ART initiation.
Looking forwards, there is a move towards recommending
earlier ART initiation. UK treatment guidelines are being
revised, and are likely to recommend ART initiation
regardless of CD4 count in light of the results of the Stra-
tegic Timing of AntiRetroviral Therapy (START) trial [25];
pregnancy guidelines are consequently expected to
change. Recently updated US pregnancy guidelines state
that ART should be considered as soon as HIV is diag-
nosed [26].
Higher parity was associated with later booking (most
notably among previously diagnosed women), a trend
also observed in the general UK population [13,15,27].
Previously diagnosed women with at least three previous
births also started ART later. Reasons are likely to be
complex. Different solutions may be required for women
who start ART late as a consequence of delayed booking
for antenatal care, and those who book for care in good
time but experience subsequent delays in ART initiation.
An audit of women in the NSHPC who received no ante-
natal ART or a short duration of ART reported that,
among those previously diagnosed, declining treatment
was the most common reason (11 of 15; 73%)[28].
Women with a prior HIV diagnosis, many of whom will
have been diagnosed during a previous pregnancy
[29,30], should be receiving ongoing HIV care, which
might be expected to facilitate early ART initiation in
subsequent pregnancies. However, we have previously
demonstrated that retention in HIV care after delivery
may be suboptimal, with two-fifths of women presenting
with a second pregnancy not being on treatment despite
an immunological indication [31]. Women not on ART at
conception booked later than those conceiving on treat-
ment, which is of concern as timely booking and prompt
referral to HIV services are needed, especially for those
with low CD4 counts. Higher levels of loss to follow-up
from HIV care have been reported among people not
receiving treatment [32], and disengagement from ser-
vices may have particularly serious consequences for
pregnant women. Although antenatal ART was started
earlier in previously diagnosed women with lower CD4
counts, in adjusted analyses there was little difference in
ART timing between those with the lowest CD4 counts
and the healthiest women. This suggests that there may
be a group of high-risk women who are poorly engaged
with care and/or suboptimally managed. It should also be
borne in mind that, although women with a CD4 count
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< 350 cells/lL should be on ART at conception, those
who are not may have concerns about initiating ART
early in pregnancy because of fears of teratogenicity.
There are some limitations to this analysis. Women can-
not book for antenatal care in the UK before they have
entered the country. Although the NSHPC collects date of
arrival in the UK, this information was completely missing
for around one-third of women born abroad. Even among
those with information reported, over half had only year
of arrival (not actual date) provided, so it was not appro-
priate to utilize this variable in the main analyses; instead,
the effect of timing of arrival on the findings was assessed
in sensitivity analyses. Week of antenatal booking was
missing for 9% of women (81% of whom had a prior HIV
diagnosis). Although only a small minority of this group
did not start ART before delivery (3.3% of those not con-
ceiving on treatment), this was higher than for women
who booked at < 13 weeks (1.1%). Some of those with
missing booking date may represent a particularly high-
risk group requiring targeted interventions to help them
engage with services. Meanwhile, earliest laboratory test
date during current pregnancy is likely to be the date on
which the sample was taken, although a minority of
NSHPC respondents may report other dates, such as the
date on which the result was reported from the laboratory.
There may have been unadjusted confounding as a result
of some variables (e.g. socioeconomic factors) not being
available in the NSHPC, which has to limit data items col-
lected to maximize reporting. Where delays in ART initia-
tion were apparent, it was not possible to assess to what
extent these were health system- or provider-related,
structural (socioeconomic environment), or related to
women’s individual circumstances, beliefs and choices.
Further exploration of this would be helpful, but is
beyond the scope of this analysis.
These analyses, based on comprehensive national data,
demonstrate significant improvements in the timeliness of
antenatal care booking and antenatal ART initiation in
the UK in recent years. However, they also reveal some
important demographic variations in access to or uptake
of care and highlight the fact that some groups of HIV-
positive women continue to face barriers to timely initia-
tion of antenatal care and ART.
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